Constitutive activation of p70 S6 kinase is associated with intrinsic resistance to cisplatin

International Journal of Oncology

Volumn 32, Issue 5, 2008, Pages 1133-1137

  Dhar, Rohini ^a   Basu, Alakananda ^a  

^a UNIVERSITY OF NORTH TEXAS HEALTH SCIENCE CENTER   (United States)

Author keywords

Apoptosis; Cisplatin; p70S6K; Small cell lung cancer

Indexed keywords

1,4 DIAMINO 1,4 BIS(2 AMINOPHENYLTHIO) 2,3 DICYANOBUTADIENE; 2 MORPHOLINO 8 PHENYLCHROMONE; CISPLATIN; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; RAPAMYCIN; S6 KINASE; 1,3 BUTADIENE DERIVATIVE; 2-(4-MORPHOLINYL)-8-PHENYL-4H-1-BENZOPYRAN-4-ONE; ANTINEOPLASTIC AGENT; CHROMONE DERIVATIVE; MITOGEN ACTIVATED PROTEIN KINASE; MORPHOLINE DERIVATIVE; NITRILE; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE INHIBITOR;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CONTROLLED STUDY; DOWN REGULATION; DRUG POTENTIATION; ENZYME ACTIVATION; ENZYME DEGRADATION; ENZYME INHIBITION; ENZYME PHOSPHORYLATION; HUMAN; HUMAN CELL; LUNG SMALL CELL CANCER; PRIORITY JOURNAL; STRAIN DIFFERENCE; DOSE RESPONSE; DRUG ANTAGONISM; DRUG EFFECT; DRUG RESISTANCE; ENZYMOLOGY; LUNG TUMOR; METABOLISM; PATHOLOGY; PHOSPHORYLATION; SMALL CELL CARCINOMA; TUMOR CELL LINE;

1-PHOSPHATIDYLINOSITOL 3-KINASE; ANTINEOPLASTIC AGENTS; APOPTOSIS; BUTADIENES; CARCINOMA, SMALL CELL; CELL LINE, TUMOR; CHROMONES; CISPLATIN; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG RESISTANCE, NEOPLASM; ENZYME ACTIVATION; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; HUMANS; LUNG NEOPLASMS; MORPHOLINES; NITRILES; PHOSPHORYLATION; POLY(ADP-RIBOSE) POLYMERASES; PROTEIN KINASE INHIBITORS; RIBOSOMAL PROTEIN S6 KINASES, 70-KDA; SIROLIMUS;

EID: 45849084692     PISSN: 10196439     EISSN: None     Source Type: Journal    
DOI: 10.3892/ijo.32.5.1133     Document Type: Article

References (42)

1. Radulovic S, Tesic Z and Manic S: Trans-platinum complexes as anticancer drugs: recent developments and future prospects. Curr Med Chem 9:1611-1618, 2002.
2. Seki K, Yoshikawa H, Shiiki K, Hamada Y, Akamatsu N and Tasaka K: Cisplatin (CDDP) specifically induces apoptosis via sequential activation of caspase-8, -3 and -6 in osteosarcoma. Cancer Chemother Pharmacol 45: 199-206, 2000.
3. Boulikas T and Vougiouka M: Recent clinical trials using cisplatin, carboplatin and their combination chemotherapy drugs (review). Oncol Rep 11: 559-595, 2004.
4. Marzano C, Bettio F, Baccichetti F, Trevisan A, Giovagnini L and Fregona D: Antitumor activity of a new platinum(II) complex with low nephrotoxicity and genotoxicity. Chemico-Biol Interact 148: 37-48, 2004.
5. Bianchi R, Gilardini A, Rodriguez-Menendez V, et al: Cisplatin-induced peripheral neuropathy: neuroprotection by erythropoietin without affecting tumour growth. Eur J Cancer 43: 710-717, 2007.
6. Rabik CA and Dolan ME: Molecular mechanisms of resistance and toxicity associated with platinating agents. Cancer Treat Rev 33: 9-23, 2007.
7. Yoon P, Giafis N, Smith J, et al: Activation of mammalian target of rapamycin and the p70 S6 kinase by arsenic trioxide in BCR-ABL-expressing cells. Mol Cancer Ther 5: 2815-2823, 2006.
8. Jefferies HBJ, Reinhard C, Kozma SC and Thomas G: Rapamycin selectively represses translation of the 'polypyrimidine tract' mRNA family. Proc Natl Acad Sci USA 91: 4441-4445, 1994.
9. Pullen N and Thomas G: The modular phosphorylation and activation of p70s6k. FEBS Lett 410: 78-82, 1997.
10. Seufferlein T and Rozengurt E: Rapamycin inhibits constitutive p70s6k phosphorylation, cell proliferation, and colony formation in small cell lung cancer cells. Cancer Res 56: 3895-3897, 1996.
11. Tee AR and Proud CG: DNA-damaging agents cause inactivation of translational regulators linked to mTOR signalling. Oncogene 19: 3021-3031,2000.
12. Tee AR and Proud CG: Staurosporine inhibits phosphorylation of translational regulators linked to mTOR. Cell Death Differ 8: 841-849,2001.
13. Wan X and Helman LJ: Effect of insulin-like growth factor II on protecting myoblast cells against cisplatin-induced apoptosis through p70 S6 kinase pathway. Neoplasia 4: 400-408, 2002.
14. Price DJ, Grove JR, Calvo V, Avruch J and Bierer BE: Rapamycin-induced inhibition of the 70-kilodalton S6 protein kinase. Science 257: 973-977, 1992.
15. Lane HA, Fernandez A, Lamb NJC and Thomas G: p70s6k function is essential for G1 progression. Nature 363: 170-172, 1993.
16. Wan X and Helman LJ: The biology behind mTOR inhibition in Sarcoma. Oncologist 12: 1007-1018, 2007.
17. Yao R and Cooper GM: Growth factor-dependent survival of rodent fibroblasts requires phosphatidylinositol 3-kinase but is independent of pp70S6K activity. Oncogene 13: 343-351, 1996.
18. McCarthy SA, Cacchione RN, Mainwaring MS and Cairns JS: The effects of immunosuppressive drugs on the regulation of activation-induced apoptotic cell death in thymocytes. Transplantation 54: 543-547, 1992.
19. DeGraffenried LA, Friedrichs WE, Russell DH, et al: Inhibition of mTOR activity restores tamoxifen response in breast cancer cells with aberrant akt activity. Clin Cancer Res 10: 8059-8067, 2004.
20. Burchert A, Wang Y, Cai D, et al: Compensatory PI3-kinase/Akt/mTor activation regulates imatinib resistance development. Leukemia 19: 1774-1782, 2005.
21. Grunwald V, DeGraffenried L, Russel D, Friedrichs WE, Ray RB and Hidalgo M: Inhibitors of mTOR reverse doxorubicin resistance conferred by PTEN status in prostate cancer cells. Cancer Res 62: 6141-6145,2002.
22. Mabuchi S, Altomare DA, Connolly DC, et al: RAD001 (Everolimus) delays tumor onset and progression in a transgenic mouse model of ovarian cancer. Cancer Res 67: 2408-2413, 2007.
23. Mabuchi S, Altomare DA, Cheung M, et al: RAD001 inhibits human ovarian cancer cell proliferation, enhances cisplatin-induced apoptosis, and prolongs survival in an ovarian cancer model. Clin Cancer Res 13: 4261-4270, 2007.
24. Beuvink I, Boulay A, Fumagalli S, et al: The mTOR inhibitor RAD001 sensitizes tumor cells to DNA-damaged induced apoptosis through inhibition of p21 translation. Cell 120: 747-759, 2005.
25. Shi Y, Frankel A, Radvanyi LG, Penn LZ, Miller RG and Mills GB: Rapamycin enhances apoptosis and increases sensitivity to cisplatin in vitro. Cancer Res 55: 1982-1988, 1995.
26. Wu C, Wangpaichitr M, Feun L, et al: Overcoming cisplatin resistance by mTOR inhibitor in lung cancer. Mol Cancer 4: 25-34, 2005.
27. Stordal B and Davey M: Understanding cisplatin resistance using cellular models. IUBMB Life 59: 696-699, 2007.
28. Moore SM, Rintoul RC, Walker TR, Chilvers ER, Haslett C and Sethi T: The presence of a constitutively active phosphoinositide 3-kinase in small cell lung cancer cells mediates anchorage-independent proliferation via a protein kinase B and p70s6k-dependent pathway. Cancer Res 58: 5239-5247, 1998.
29. Kamata S, Kishimoto T, Kobayashi S, Miyazaki M and Ishikura H: Possible involvement of persistent activity of the mammalian target of rapamycin pathway in the cisplatin resistance of AFP-producing gastric cancer cells. Cancer Biol Ther 6, 2007.
30. Liu LZ, Zhou XD, Qian G, Shi X, Fang J and Jiang BH: AKT1 amplification regulates cisplatin resistance in human lung cancer cells through the mammalian target of rapamycin/p70S6K1 pathway. Cancer Res 67: 6325-6332, 2007.
31. Dennis PB, Pullen N, Pearson RB, Kozma SC and Thomas G: Phosphorylation sites in the autoinhibitory domain participate in p70(s6k) activation loop phosphorylation. J Biol Chem 273: 14845-14852, 1998.
32. Pearson RB, Dennis PB, Han JW, et al: The principal target of rapamycin-induced p70s6k inactivation is a novel phosphorylation site within a conserved hydrophobic domain. EMBO J 14: 5279-5287, 1995.
33. Boulares AH, Yakovlev AG, Ivanova V, et al: Role of poly(ADP-ribose) polymerase (PARP) cleavage in apoptosis. Caspase 3-resistant PARP mutant increases rates of apoptosis in transfected cells. J Biol Chem 274: 22932-22940, 1999.
34. Jefferies HB, Fumagalli S, Dennis PB, Reinhard C, Pearson RB and Thomas G: Rapamycin suppresses 5′TOP mRNA translation through inhibition of p70s6k. EMBO J 16: 3693-3704, 1997.
35. Meng Q, Xia C, Fang J, Rojanasakul Y and Jiang B-H: Role of PI3K and AKT specific isoforms in ovarian cancer cell migration, invasion and proliferation through the p70S6K1 pathway. Cell Signal 18: 2262-2271, 2006.
36. Houghton PJ and Huang S: mTOR as a target for cancer therapy. Curr Top Microbiol Immunol 279: 339-359, 2004.
37. Dufner A, Andjelkovic M, Burgering BMT, Hemmings BA and Thomas G: Protein kinase B localization and activation differentially affect S6 kinase 1 activity and eukaryotic translation initiation factor 4E-binding protein 1 phosphorylation. Mol Cell Biol 19: 4525-4534, 1999.
38. Shi Y, Hsu JH, Hu L, Gera J and Lichtenstein A: Signal pathways involved in activation of p70S6K and phosphorylation of 4E-BP1 following exposure of multiple myeloma tumor cells to interleukin-6. J Biological Chem 277: 15712-15720, 2002.
39. Lee DF, Kuo HP, Chen CT, et al: IKK beta suppression of TSC 1 links inflammation and tumor angiogenesis via the mTOR pathway. Cell 130: 440-455, 2007.
40. Ikezoe T, Nishioka C, Bandobashi K, et al: Longitudinal inhibition of PI3K/Akt/mTOR signaling by LY294002 and rapamycin induces growth arrest of adult T-cell leukemia cells. Leuk Res 31: 673-682, 2007.
41. Gervais M, Dugourd C, Muller L, et al: Akt down-regulates ERK1/2 nuclear localization and angiotensin II-induced cell proliferation through PEA-15. Mol Biol Cell 17: 3940-3951, 2006.
42. Basu A and Tu H: Activation of ERK during DNA damage-induced apoptosis involves protein kinase Cdelta. Biochem Biophys Res Commun 334: 1068-1073, 2005.